Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center.

@article{Denis1998MaximalAB,
  title={Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center.},
  author={Louis Jean Denis and Frans I Keuppens and Philip W. Smith and Peter J Whelan and J L Carneiro de Moura and Don W.W. Newling and A. G. de Bono and Richard Sylvester},
  journal={European urology},
  year={1998},
  volume={33 2},
  pages={144-51}
}
OBJECTIVES This prospective, randomized phase III study was initiated to compare the efficacy and side effects of bilateral orchiectomy versus a combination of a luteinizing hormone-releasing hormone agonist depot formulation, goserelin acetate (3.6 mg s.c. once every 4 weeks) and flutamide (250 mg 3 x daily) in patients with metastatic prostate cancer. METHODS Relative treatment efficacy was assessed by comparing the two treatment groups with respect to response, time to first progression… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

Similar Papers

Loading similar papers…